Skip to main content

GW Pharma stock jumps to record after DEA stance on its CBD drug, cannabis sector lags

Shares of GW Pharmaceuticals PLC surged to a record high Thursday, after the medical-marijuana company announced a new Drug Enforcement Administration stance on its approved drug containing cannabidiol, or CBD.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.